Vivesto AB
Research Vivesto AB (VIVE) on Bullrun: market cap SEK 98.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIVE
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencySEK
- Market capSEK 98.09M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 6.89M
- Free cash flow-SEK 6.46M
Valuation Snapshot
latest market cap is SEK 98.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 34.08M | -SEK 38.81M | n/a | -0.06 | SEK 2.03M | SEK 13.00M | SEK 124.58M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | SEK 98.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vivesto AB's market cap?
Vivesto AB's market capitalization is SEK 98.09M.
What does Vivesto AB do?
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer.